Nektar Therapeutics (NKTR) Misses Q1 EPS by 182c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($1.82). Revenue for the quarter came in at $10.9 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Therapeutics files for proposed IPO
- Nomura/Instinet Starts Lenskart Solutions (LENSKART:IN) at Buy
- Axis Capital Limited Upgrades Blue Star Limited (BLSTR:IN) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
